US › Healthcare

MacroGenics Inc (MGNX)

US · Healthcare · Biotechnology

$4.13+1.23%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$32.8M

Revenue YoY

+47.6%

Net profit

$19.5M

EPS

$-0.27

EPS estimate

$-0.34

Net margin

59.4%

EPS came in at -0.27 against a street estimate of -0.34 — a beat of 20.6%.

Key statistics

Market cap

$254.8M

Forward P/E

61.0

P/B

5.90

Book value

$0.67

EPS (TTM)

$-1.59

52-week high

$5.08

52-week low

$1.29

50-day MA

$4.16

200-day MA

$3.06

Beta

1.23

Analyst view

Analysts rate MacroGenics Inc a buy (3 buy, 4 hold, 0 sell out of 7) with an average price target of $8.00.

Shareholding

Insiders

3.48%

Institutions

77.54%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	9.44%
Renaissance Technologies Corp	4.65%
Vanguard Capital Management, LLC	4.17%
Acadian Asset Management LLC	3.99%
Two Sigma Investments LLC	3.97%
Bank of America Corp	3.77%
Millennium Management LLC	3.73%
Marshall Wace Asset Management Ltd	3.18%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MacroGenics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.